Home » Stocks » RVMD

Revolution Medicines, Inc. (RVMD)

Stock Price: $38.74 USD -1.58 (-3.92%)
Updated Apr 19, 2021 10:46 AM EDT - Market open
Market Cap 2.96B
Revenue (ttm) 42.98M
Net Income (ttm) -110.38M
Shares Out 54.87M
EPS (ttm) -21.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $38.74
Previous Close $40.32
Change ($) -1.58
Change (%) -3.92%
Day's Open 39.93
Day's Range 38.74 - 40.71
Day's Volume 66,456
52-Week Range 21.17 - 56.18

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Revolution Medicines' leading compound is shaping up to be a platform in a pill.

Other stocks mentioned: AZN, MRK, MRTX, RHHBY, SNY
2 weeks ago - The Motley Fool

Presentations Highlight Continued Progress Across Expanded R&D Pipeline of RAS(ON) Inhibitors and RAS Companion Inhibitors Presentations Highlight Continued Progress Across Expanded R&D Pipeline of RAS(...

1 month ago - GlobeNewsWire

REDWOOD CITY, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets ...

1 month ago - GlobeNewsWire

Advanced and Expanded Portfolio of RAS(ON) Inhibitors; Two Assets Entered IND-Enabling Development

1 month ago - GlobeNewsWire

Steve Kelsey, M.D., President, Research and Development, to Present its Pioneering RAS(ON) Inhibitors and Participate in Panel Discussion Steve Kelsey, M.D., President, Research and Development, to Pres...

2 months ago - GlobeNewsWire

Underwriters' Full Exercise of Option Brings Gross Proceeds to $300 Million

2 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD) today announced the pricing of its underwritten public offering of 5,797,101 shares of common stock at a...

2 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD) today announced that it has commenced an underwritten public offering of 4,000,000 shares of common stoc...

2 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets i...

3 months ago - GlobeNewsWire

Revolution Medicines (NASDAQ: RVMD) shares are trading higher on Thursday after the company reported a third-quarter EPS loss of 42 cents, up from a loss of $6.08 year-over-year and sales $12.66 million...

5 months ago - Benzinga

Recommended Phase 2 Dose and Schedule Selected for Further Evaluation of RMC-4630 as Monotherapy and RMC-4630 plus Cobimetinib Combination

5 months ago - GlobeNewsWire

Plenary Presentation at EORTC-NCI-AACR 3 2 nd Symposium on Molecular Targets and Cancer Therapeutics Describes Encouraging Tolerability and Exposure Profile s for RMC-4630 Combined with Cobimetinib and ...

5 months ago - GlobeNewsWire

Study Findings Selected for Oral Presentation in Plenary Session at EORTC-NCI-AACR 32nd Symposium on Molecular Targets and Cancer Therapeutics Study Findings Selected for Oral Presentation in Plenary Se...

6 months ago - GlobeNewsWire

Revolution Medicines (RVMD) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

6 months ago - Zacks Investment Research

Presentation at 2nd Annual RAS-Targeted Drug Development Conference Highlights First Publicly Reported Data for Inhibitors of Notorious Cancer Protein KRASG12D(ON)

7 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit fron...

7 months ago - GlobeNewsWire

Company’s Scientific Leadership to Deliver Presentations, Participate in Panel Discussion and Co-Lead Workshop During Digital Event Company’s Scientific Leadership to Deliver Presentations, Participate ...

7 months ago - GlobeNewsWire

Interim RMC-4630 Data Support Benefit of Intermittent Dosing and Corroborate Clinical Activity Against Genetically-Defined Tumors

8 months ago - GlobeNewsWire

Underwriters’ Full Exercise of Option Brings Gross Proceeds to $179.4 Million Underwriters’ Full Exercise of Option Brings Gross Proceeds to $179.4 Million

9 months ago - GlobeNewsWire

Revolution Medicines (RVMD) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.

9 months ago - Zacks Investment Research

REDWOOD CITY, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD) today announced the pricing of its underwritten public offering of 6,000,000 shares of common stock at ...

9 months ago - GlobeNewsWire

REDWOOD CITY, Calif., July 06, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD) today announced that it has commenced an underwritten public offering of 5,500,000 shares of common sto...

9 months ago - GlobeNewsWire

Newly Discovered Natural Product and Designed Analogues Bind to Human Protein that is Exploited by the SARS-CoV-2 Virus Newly Discovered Natural Product and Designed Analogues Bind to Human Protein that...

9 months ago - GlobeNewsWire

REDWOOD CITY, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer...

9 months ago - GlobeNewsWire

Combination of Investigational SHP2 Inhibitor and Anti-PD-1 Antibody to be Evaluated in Patients with Solid Tumors Combination of Investigational SHP2 Inhibitor and Anti-PD-1 Antibody to be Evaluated in...

9 months ago - GlobeNewsWire

REDWOOD CITY, Calif., June 18, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer...

10 months ago - GlobeNewsWire

Study Evaluates Combination Treatment with Investigational SHP2 and KRASG12C Inhibitors in Patients with KRASG12C Mutant Solid Tumors

10 months ago - GlobeNewsWire

Stocks are firing on all cylinders again and have clawed back most of their bear-market losses.

Other stocks mentioned: AMAT, BABA, BBIO, GH, LLNW, PLUG
10 months ago - Kiplinger

Company to Host R&D Update Conference Call Following AACR Meeting Company to Host R&D Update Conference Call Following AACR Meeting

11 months ago - GlobeNewsWire

Closed Initial Public Offering Raising Gross Proceeds of $273.7 Million

11 months ago - GlobeNewsWire

Findings Support Plans to Expand Clinical Evaluation of RMC-4630, the Company’s Investigational SHP2 Inhibitor, to Include Combination with Anti-PD-1 Drug Findings Support Plans to Expand Clinical Evalu...

11 months ago - GlobeNewsWire

Multi-cohort Phase 1/2 Clinical Program Currently Evaluating RMC-4630 Multi-cohort Phase 1/2 Clinical Program Currently Evaluating RMC-4630

1 year ago - GlobeNewsWire

Netherlands Cancer Institute Intends to Sponsor and Conduct Phase 1/1b SHERPA Trial in Patients with Tumors Harboring RAS Mutations Netherlands Cancer Institute Intends to Sponsor and Conduct Phase 1/1b...

1 year ago - GlobeNewsWire

Revolution Should Be On Your Radar; 'Undruggable Targets' Now Potentially Druggable

1 year ago - Seeking Alpha

Shares of cancer-specialist Revolution Medicines soared on its first day of public trading.

1 year ago - The Motley Fool

The share price of a clinical-stage oncology company that went public just last week has climbed more than 70% on hopes that it can develop drugs to transform the way cancer is treated.

Other stocks mentioned: AMGN, MRTX
1 year ago - GuruFocus

REDWOOD CITY, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive frontie...

1 year ago - GlobeNewsWire

Revolution Medicines Inc. (NASDAQ: RVMD) entered the market with a bang on Thursday.

1 year ago - 24/7 Wall Street

Shares of Revolution Medicines Inc. , a clinical-stage oncology company, soared 85% Thursday in their trading debut, after underwriters priced the initial public offering at the top end of a revised range.

1 year ago - Market Watch

About RVMD

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the... [Read more...]

Industry
Biotechnology
IPO Date
Feb 13, 2020
CEO
Mark Goldsmith
Employees
125
Stock Exchange
NASDAQ
Ticker Symbol
RVMD
Full Company Profile

Financial Performance

In 2020, RVMD's revenue was $42.98 million, a decrease of -14.10% compared to the previous year's $50.04 million. Losses were -$108.16 million, 126.9% more than in 2019.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for RVMD stock is "Buy." The 12-month stock price forecast is 54.00, which is an increase of 39.39% from the latest price.

Price Target
$54.00
(39.39% upside)
Analyst Consensus: Buy